Mediclarum
Medicine guide

Methocarbamol

750 mg · Tablet, Film Coated

  • Prescription only
  • Muscle Relaxant
Active substance
Methocarbamol
Made by
Sportpharm LLC

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

At a glance

Quoted from the official label · 2026-04-03

What it is

Muscle Relaxant

Used for
  • Methocarbamol tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.
The label’s usual adult dose

Methocarbamol tablets, 500 mg - Adults: Initial dosage: 3 tablets 4 times daily.

Full directions ↓
Do not take it if

Methocarbamol tablets are contraindicated in patients hypersensitive to methocarbamol or to any of the tablet components.

All warnings ↓
Good to know
  • Prescription only
  • FDA enforcement reports list no ongoing recall, and none from the last two years, for this product code · checked 2026-10-02
118other products contain Methocarbamol — compare makers, forms and strengths

Every line above is selected, not written, from the official label. Nothing is reworded. DailyMed

What it is for

  • Methocarbamol tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.
  • The mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties.
  • Methocarbamol does not directly relax tense skeletal muscles in man.

From the official label · 2026-04-03 · DailyMed

How it works

From this product’s own US prescribing label.

The mechanism of action of methocarbamol in humans has not been established, but may be due to general CNS depression.

It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.

Half-life1–2 h
Mostly cleared after≈ 7.5 hfive half-lives — our arithmetic
How the body breaks it down

Methocarbamol is metabolized via dealkylation and hydroxylation.

How it leaves the body

Essentially all methocarbamol metabolites are eliminated in the urine.

Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-04-03

Do not take it if

Methocarbamol tablets are contraindicated in patients hypersensitive to methocarbamol or to any of the tablet components.

Quoted from the official label, section “Contraindications”.

How to take it

These directions are for this exact strength and form. Another one is different.

  • Methocarbamol tablets, 500 mg - Adults: Initial dosage: 3 tablets 4 times daily.
  • Maintenance dosage: 2 tablets 4 times daily.
  • Methocarbamol tablets: 750 mg - Adults: Initial dosage: 2 tablets 4 times daily.
  • Maintenance dosage: 1 tablet q.4h. or 2 tablets 3 times daily.
  • Six grams a day are recommended for the first 48 to 72 hours of treatment.
  • (For severe conditions 8 grams a day may be administered.) Thereafter, the dosage can usually be reduced to approximately 4 grams a day.

Quoted from the official label, section “Dosage & Administration”.

Other warnings

  • Since methocarbamol may possess a general CNS depressant effect, patients receiving methocarbamol should be cautioned about combined effects with alcohol and other CNS depressants.
  • Therefore, methocarbamol should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see PRECAUTIONS , Pregnancy ).
  • Use in Activities Requiring Mental Alertness Methocarbamol may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle.
  • Patients should be cautioned about operating machinery, including automobiles, until they are reasonably certain that methocarbamol therapy does not adversely affect their ability to engage in such activities.
  • Information for Patients Patients should be cautioned that methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery.
  • Drug Interactions See WARNINGS and PRECAUTIONS for interaction with CNS drugs and alcohol.
  • Drug/Laboratory Test Interactions Methocarbamol may cause a color interference in certain screening tests for 5-hydroxyindoleacetic acid (5-HIAA) using nitrosonaphthol reagent and in screening tests for urinary vanillylmandelic acid (VMA) using the Gitlow method.
  • Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies to evaluate the carcinogenic potential of methocarbamol have not been performed.
  • No studies have been conducted to assess the effect of methocarbamol on mutagenesis or its potential to impair fertility.
  • Pregnancy Teratogenic Effects Animal reproduction studies have not been conducted with methocarbamol.
  • Nursing Mothers Methocarbamol and/or its metabolites are excreted in the milk of dogs; however, it is not known whether methocarbamol or its metabolites are excreted in human milk.
  • Pediatric Use Safety and effectiveness of methocarbamol in pediatric patients below the age of 16 have not been established.

Quoted from the official label, section “Warnings”.

Pregnancy and breastfeeding

  • Teratogenic Effects Animal reproduction studies have not been conducted with methocarbamol.
  • It is also not known whether methocarbamol can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.
  • Methocarbamol should be given to a pregnant woman only if clearly needed.
  • Safe use of methocarbamol has not been established with regard to possible adverse effects upon fetal development.
  • There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol.
  • Therefore, methocarbamol should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see WARNINGS ).
  • Methocarbamol and/or its metabolites are excreted in the milk of dogs; however, it is not known whether methocarbamol or its metabolites are excreted in human milk.
  • Because many drugs are excreted in human milk, caution should be exercised when methocarbamol is administered to a nursing woman.

Quoted from the official label, section “OTC — Pregnancy or Breast Feeding”.

Other medicines

  • See WARNINGS and PRECAUTIONS for interaction with CNS drugs and alcohol.
  • Methocarbamol may inhibit the effect of pyridostigmine bromide.
  • Therefore, methocarbamol should be used with caution in patients with myasthenia gravis receiving anticholinesterase agents.

Quoted from the official label, section “Drug Interactions”.

If you take too much

In an emergency, call your local emergency number or a poison control centre.

  • Limited information is available on the acute toxicity of methocarbamol.
  • Overdose of methocarbamol is frequently in conjunction with alcohol or other CNS depressants and includes the following symptoms:
  • nausea, drowsiness, blurred vision, hypotension, seizures, and coma.
  • In post-marketing experience, deaths have been reported with an overdose of methocarbamol alone or in the presence of other CNS depressants, alcohol or psychotropic drugs.
  • Treatment Management of overdose includes symptomatic and supportive treatment.
  • Supportive measures include maintenance of an adequate airway, monitoring urinary output and vital signs, and administration of intravenous fluids if necessary.
  • The usefulness of hemodialysis in managing overdose is unknown.

Quoted from the official label, section “Overdosage”.

Use in children

Safety and effectiveness of methocarbamol in pediatric patients below the age of 16 have not been established.

Quoted from the official label, section “Pediatric Use”.

Side effects

  • Adverse reactions reported coincident with the administration of methocarbamol include:
  • Body as a whole:
  • Anaphylactic reaction, angioneurotic edema, fever, headache Cardiovascular system:
  • Bradycardia, flushing, hypotension, syncope, thrombophlebitis Digestive system:
  • Dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting Hemic and lymphatic system:
  • Leukopenia Immune system:
  • Hypersensitivity reactions Nervous system:
  • Amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigo Skin and special senses:
  • Blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, urticaria

Quoted from the official label, section “Adverse Reactions”.

What to discuss with your doctor

  • Patients should be cautioned that methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery.
  • Because methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants.

Quoted from the official label, section “Patient Counseling Information”.

What it looks like and how it is packed

  • Methocarbamol Tablets USP, 750 mg are white in color, biconvex capsule shaped film-coated tablet, debossed with “METT” on one side and “750” on the other side.
  • They are supplied as follows:
  • Bottles of 21 NDC 85766-060-21 (repackaged from NDC 59651-341-XX) Bottles of 28 NDC 85766-060-28 (repackaged from NDC 59651-341-XX) Bottles of 30 NDC 85766-060-30 (repackaged from NDC 59651-341-XX) Bottles of 42 NDC 85766-060-42 (repackaged from NDC 59651-341-XX) Bottles of 60 NDC 85766-060-60 (repackaged from NDC 59651-341-XX) Bottles of 90 NDC 85766-060-90 (repackaged from NDC 59651-341-XX) Bottles of 100 NDC 85766-060-01 (relabeled from NDC 59651-341-01) Bottles of 500 NDC 85766-060-05 (relabeled from NDC 59651-341-05)
  • Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
  • Dispense in tight container.
  • For more information, call Aurobindo Pharma USA, Inc.at 1-866-850-2876.
  • Distributed by:
  • Sportpharm 2237 N Commerce Parkway, STE 1, Weston, Florida-33326 Relabeled and Repackaged by:
  • Enovachem PHARMACEUTICALS Torrance, CA 90501

Quoted from the official label, section “How Supplied”.

What is in it

  • Methocarbamol tablets, USP, a carbamate derivative of guaifenesin, is a central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties.
  • The chemical name of methocarbamol is 3-(2-methoxyphenoxy)-1,2-propanediol 1-carbamate and has the empirical formula C 11 H 15 NO 5 .
  • Its molecular weight is 241.24.
  • The structural formula is shown below.
  • Methocarbamol is a white bulky powder, sparingly soluble in water and chloroform, soluble in alcohol only with heating and insoluble in benzene and n -hexane.
  • Methocarbamol tablets USP, 750 mg are available as white in color, biconvex capsule shaped film-coated tablet containing 750 mg of methocarbamol USP for oral administration.
  • Methocarbamol tablets USP, 750 mg contain the following inactive ingredients:
  • corn starch, hypromellose, magnesium stearate, polyethylene glycol, povidone, sodium lauryl sulfate, sodium starch glycolate, talc and titanium dioxide.
  • Chemical Structure

Quoted from the official label, section “Description”.

Ingredients people check for

Lactose, gluten, dyes, sugars and other ingredients that matter with an allergy, intolerance or diet — as this product’s FDA label lists them.

  • Titanium dioxidetitanium dioxideA whitening agent no longer allowed in food in the EU (E171).

Quoted from the FDA label. A label that does not name an ingredient is not a guarantee that the product is free of it, and formulations change. With an allergy, check the pack and ask a pharmacist.

Every version of this medicine (48)

The same active substance, strength and kind of form, from every company that sells it — with what each label lists.

Hide versions whose label lists:

Showing 48 of 48

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

Canada1 matching products

Every strength and form (1)

Details

Made bySportpharm LLC
Active substanceMethocarbamol
Used inMuscles, joints and bones
Strength750 mg
FormTablet, Film Coated
RouteOral
Packs100 TABLET, FILM COATED in 1 BOTTLE · 500 TABLET, FILM COATED in 1 BOTTLE
NDC85766-060

Source: NDC Directory · 2026-09-13 · not reviewed by a clinician

Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).

Report wrong or outdated information on this page

Other strengths and forms

139 products are sold under this name. Grouped by form; a number on a strength means several companies make it.

Show all forms · 5 forms

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.

Atmeksi750 mg/5mLPrescription onlySuspension Rosemont Pharmaceuticals LLC · MethocarbamolMethocarb 500-EzsPrescription onlyKit PureTek Corporation · MethocarbamolMethocarbamol1000 mgPrescription onlyTablet, Coated Misemer Pharmaceutical · MethocarbamolMethocarbamol1000 mg/10mLPrescription onlyInjection, Solution Henry Schein, Inc · MethocarbamolMethocarbamol500 mgPrescription onlyTablet, Film Coated NCS HealthCare of KY, LLC dba Vangard Labs · MethocarbamolMethocarbamol750 mgPrescription onlyTablet, Film Coated NCS HealthCare of KY, LLC dba Vangard Labs · Methocarbamol

See every product with Methocarbamol